Seminars in pediatric neurology
June 21, 2025 · via Europe PMC
Subacute sclerosing panencephalitis.
Gunasekaran PK, Saini AG.
AI summary — for doctors, generated from the abstract only
This review describes subacute sclerosing panencephalitis as a fatal, delayed complication of measles infection that remains a major public health crisis in low- and middle-income countries due to inadequate vaccine coverage and limited diagnostic infrastructure, while new molecular treatment approaches remain largely inaccessible in these settings.
What was studied
This is a review article covering subacute sclerosing panencephalitis (SSPE), a progressive, fatal neurodegenerative disorder caused by persistent mutated measles virus infection, discussing its pathophysiology, clinical course, the public health challenges driving its persistence in low- and middle-income countries (LMICs), and emerging but largely inaccessible therapeutic strategies.
Key findings
- SSPE typically leads to progressive behavioral and cognitive decline, neuromotor impairment, myoclonus, vegetative state, and death within 1-3 years of diagnosis, though prolonged stabilization or spontaneous resolution occurs in a minority of patients
- Despite global measles elimination efforts, SSPE remains a challenging problem in LMICs due to inadequate vaccine coverage, limited health infrastructure, suboptimal surveillance, and limited diagnostic test availability
- Measles outbreaks in high-income countries with developed vaccination programs are commonly linked to international travel, immigration, and vaccine hesitancy, making measles elimination (and SSPE prevention) a global challenge
- No effective antiviral therapy currently exists, making supportive and palliative care the primary management strategy once SSPE is confirmed, while emerging molecular therapeutic approaches remain largely inaccessible in measles-endemic LMICs
Clinical relevance
The findings suggest that preventing SSPE fundamentally depends on strengthening measles vaccination coverage and surveillance, particularly in LMICs where the disease burden is highest, and that current treatment remains limited to supportive and palliative care given the absence of effective antiviral therapy, which the authors suggest underscores the urgent need for strengthened vaccination programs and improved access to emerging diagnostics and treatments globally.
Who should care
Limitations
As a narrative review, it does not report original epidemiologic or outcome data, specific statistics on disease burden by region, or a systematic search methodology in the available abstract text.
This review highlights subacute sclerosing panencephalitis as a fatal, largely preventable complication of measles that remains a public health crisis in under-vaccinated low- and middle-income countries, with no effective antiviral treatment currently available anywhere, underscoring the urgent need for stronger global vaccination efforts.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Subacute sclerosing panencephalitis (SSPE) is a devastating neurodegenerative disorder due to a persistent mutated, wild-measles virus infection of the nervous system. While the acute infection is generally self-limiting, defective viral clearance can lead to the emergence of neurovirulent strains that undergo mutations within the host, evade immune surveillance, establishing chronic central nervous system (CNS) infection. It predominantly affects children and young adults although no age, including infants, is immune to SSPE. The characteristic neurological manifestations include progressive behavioral and cognitive decline, neuromotor impairment, myoclonus, vegetative state and death within 1-3 years of diagnosis, although prolonged stabilization and spontaneous resolution have been reported in a minority of patients. Despite global efforts towards measles elimination, SSPE remains a challenging problem in the low- and middle-income countries (LMICs) due to inadequate vaccine coverage. Limited health infrastructure, suboptimal surveillance, and limited availability of diagnostic tests hinders early diagnosis and management making SSPE a public health crisis. The measles outbreaks in high-income countries with developed vaccination programs are commonly due to international travel, immigration, and vaccine hesitancy, making it a global problem. The lack of effective antiviral therapy makes supportive and palliative care the primary management strategy once SSPE is confirmed. Recent research highlights potential therapeutic strategies, novel molecular approaches targeting mutant measles viruses, and enhanced public health measures to contain the outbreaks. However, these remain largely inaccessible in LMICs with measles endemicity and the high disease burden of SSPE. Urgent action is needed to bridge this gap by strengthening vaccination programs, implementing early diagnostic strategies, and enhancing access to emerging treatments. The current review discusses the various aspects of SSPE and the importance of preventive strategies for SSPE as relevant to LMIC. Without holistic efforts and a multi-pronged approach to eliminate measles and prevent SSPE, the disease shall remain a global threat.
DOI
10.1016/j.spen.2025.101207
PMID
40701692
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed